Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ikena Oncology Inc (NQ: IKNA )

1.710 +0.010 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ikena Oncology Inc

< Previous 1 2 3 4 5 Next >
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Optimism Surrounds Cancer Focused Ikena Oncology, Analyst Initiates With Outperform
Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.  
Via Benzinga
Ikena Oncology to Participate in September 2023 Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Analyst Ratings for Ikena Oncology
Via Benzinga
Credit Suisse Maintains Outperform Rating for Ikena Oncology: Here's What You Need To Know
Via Benzinga
Ikena Oncology Earnings Perspective: Return On Capital Employed
Via Benzinga
Ikena Oncology's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a look at all of the biggest pre-market stock movers worth keeping an eye on for Tuesday! 
Via InvestorPlace
Ikena Oncology Acquires Pionyr Immunotherapeutics: Analysts See The Deal As Positive Move
Ikena Oncology Inc (NASDAQ: IKNA) acquired Pionyr Immunotherapeutics Inc, a privately-held biotechnology company, in  
Via Benzinga
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Upcoming Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces $40 Million Underwritten Offering
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ikena Oncology Appoints Owen Hughes as Board Chair
From Ikena Oncology, Inc.
Via GlobeNewswire
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer
Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway. 
Via Benzinga
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.